Skip to main content

Table 3 Key headache baseline characteristics of Non-Responders and Super-Responders to CGRP(-R) mAbs

From: Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience

 

Non-Responders

MD

Super-Responders

MD

P value

Number of MHDs, mean ± SD

18.2 ± 6.8

-

11.4 ± 4.5

-

 < 0.001*

Number of MMDs, mean ± SD

14.1 ± 6.4

4

10.6 ± 4.7

4

 < 0.035*

Chronic migraine, n (%)

24 (92%)

-

15 (48%)

-

0.001*

Aura, n (%)

8 (15%)

-

13 (24%)

-

0.356

Intensity 1–10, mean ± SD

7.2 ± 1.9

1

7.0 ± 2.2

2

0.729

Attack duration (h),

mean ± SD

44.2 ± 26.6

10

31.5 ± 28.7

7

0.172

Unilateral headache, n (%)

18 (72%)

1

25 (93%)

2

0.129

Pulsating character, n (%)

19 (76%)

1

26 (93%)

1

0.231

Aggravation by physical activity, n (%)

22 (100%)

4

25 (100%)

4

0.867

Photophobia, n (%)

21 (88%)

2

26 (96%)

2

0.503

Phonophobia, n (%)

20 (87%)

3

24 (89%)

2

0.818

Nausea, n (%)

21 (88%)

2

27 (100%)

2

0.166

Vomitus, n (%)

4 (18%)

4

12 (48%)

4

0.031*

  1. Abbr.: MHD Monthly Headache Days, MMD Monthly Migraine Days, SD Standard deviation, MD Missing data
  2. * Statistically significant